en ENGLISH
eISSN: 2300-8660
ISSN: 0031-3939
Pediatria Polska - Polish Journal of Paediatrics
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Bazy indeksacyjne Kontakt Zasady publikacji prac Standardy etyczne i procedury
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
SCImago Journal & Country Rank
3/2021
vol. 96
 
Poleć ten artykuł:
Udostępnij:
streszczenie artykułu:
Artykuł przeglądowy

Transplant-associated thrombotic microangiopathy

Tomasz Jarmoliński
1, 2

  1. Department of Bone Marrow Transplantation, Oncology and Paediatric Hematology, Wroclaw Medical University, Wroclaw, Poland
  2. Children’s Division, Five Holy Brothers Miedzyrzecki Hospital in Miedzyrzecz, Poland
Pediatr Pol 2021; 96 (3): 207–212
Data publikacji online: 2021/09/29
Pełna treść artykułu Pobierz cytowanie
 
Metryki PlumX:


Transplant-associated thrombotic microangiopathy (TA-TMA), which is a severe and quite frequent complication of hematopoietic stem cell transplantation (HSCT) in children, significantly influences patients’ overall survival. Endothelial damage plays a central role in pathogenesis and overactivation of complement resulting in high plasma concentration of C5b-9 acts as the key driver. The clinical picture consists of combination of nonimmunologic hemolytic anemia, thrombocytopenia and organ damage. The diagnosis, which is based on laboratory criteria, is difficult since they overlap symptoms of other HSCT complications: graft versus host disease, infections and drug toxicities. No efficacious treatment had been available till recent years when anti-complement therapy was introduced. Using of C5-blocking humanized antibodies eculizumab brought breakthrough improvement of 1-year post-transplant survival in high-risk TA-TMA which increased from 17 to 64%. To achieve optimal results the therapy should be modified according to pharmacokinetic and pharmacodynamic parameters. Other complement-targeted agents, ravulizumab and coversin, are currently being tested.